A case report of ischemic bowel disease caused by Shengxuexiaoban capsules

Published on Feb. 28, 2025Total Views: 504 times Total Downloads: 63 times Download Mobile

Author: XU Cuilin ^1, ² LI Binbin ^2, ³ HU Jing ⁴ HU Naizhong ⁴  WANG Yanyan ²

Affiliation: 1. Department of Pharmacy, Bozhou Hospital of Traditional Chinese Medicine, Bozhou 236800, Anhui Province, China 2. Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University, Hefei 230000, China 3. Department of Pharmacy, the First People's Hospital of Yulin, Yulin 537000, Guangxi Zhuang Autonomous Region, China 4. Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University, Hefei 230000, China

Keywords: Shengxuexiaoban capsules Ischemic bowel disease Adverse reactions

DOI: 10.12173/j.issn.1005-0698.202408096

Reference: XU Cuilin, LI Binbin, HU Jing, HU Naizhong, WANG Yanyan. A case report of ischemic bowel disease caused by Shengxuexiaoban capsules[J]. Yaowu Liuxingbingxue Zazhi, 2025, 34(2): 236-240. DOI: 10.12173/j.issn.1005-0698.202408096.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

A 76-year-old male patient with lung cancer developed thrombocytopenia due to chemotherapy. Three days after taking the Shengxuexiaoban capsules orally, he experienced abdominal pain and bloody stool and was admitted to the hospital. The blood test showed white blood cell count of 11.54×10⁹·L^-1, neutrophil percentage of 82.4%, platelet count of 93×10^⁹·L^-1, and C-reactive protein level of 23.50 mg·L^-1. Fecal occult blood test positive, and pathology indicatesd ischemic-like changes in the rectal mucosa. The patient was diagnosed with ischemic bowel disease. After treatment with fluid replacement and anti-infection, the patient's abdominal pain disappeared and his stool turned yellow. The Naranjo’s Assessment Scale was used to evaluate the association between adverse effects of ischemic bowel disease and Shengxuexiaoban capsules, and the result was very likely related. This article analysed the clinical characteristics and drug treatment process of ischemic bowel disease caused by Shengxuexiaoban capsule through this case, aiming to provide references for the safe use of drugs in the clinically.

Full-text

Please download the PDF version to read the full text: download

References

1.胡崇晖, 姜泊, 蒋绚, 等. 缺血性肠病的危险因素及其诊治研究进展[J]. 山东医药, 2024, 64(16): 102-105. [Hu CH, Jiang B, Jiang X, et al. Risk factors and advances in the diagnosis and treatment of ischemic bowel disease[J]. Shandong Medicine, 2024, 64(16): 102-105.] DOI: 10.3969/j.issn.1002-266X.2024.16.026.

2.张坤良. 缺血性肠病的临床特征及影响因素分析[J]. 中国实用医药, 2021, 16(26): 41-43. [Zhang KL. Clinical features and analysis of influencing factors of ischemic intestinal disease[J]. Chinese Journal of Practical Medicine, 2021, 16(26): 41-43.] DOI: 10.14163/j.cnki.11-5547/r.2021.26.015.

3.吴本俨, 王刚石, 杨云生. 老年人结肠缺血诊治中国专家指导意见[J]. 中华内科杂志, 2023, 62(6): 639-646. [Wu BY, Wang GS, Yang YS. Diagnosis and treatment of elderly colonic ischemia: Chinese Expert Consensus[J]. Chinese Journal of Internal Medicine, 2023, 62(6): 639-646.] DOI: 10.3760/cma.j.cn112138-20220601-00421.

4.Montoro MA, Brandt LJ, Santolaria S, et al. Clinical patterns and outcomes of ischaemic colitis: results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study) [J]. Scand J Gastroenterol, 2011, 46(2): 236-246. DOI: 10.3109/00365521.2010.525794.

5.Doulberis M, Panagopoulos P, Scherz S, et al. Update on ischemic colitis: from etiopathology to treatment including patients of intensive care unit[J]. Scand J Gastroenterol, 2016, 51(8): 893-902. DOI: 10.3109/00365521.2016.1162325.

6.Xu Y, Xiong L, Li Y, et al. Diagnostic methods and drug therapies in patients with ischemic colitis[J]. Int J Colorectal Dis, 2021, 36(1): 47-56. DOI: 10.1007/s00384-020-03739-z.

7.Cheng Y, Fan Y, Zhao Y, et al. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial[J]. J Thorac Oncol, 2024, 19(7): 1073-1085. DOI: 10.1016/j.jtho.2024.03.008.

8.Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and Meta-analysis[J]. JAMA Oncol, 2019, 5(7): 1008-1019. DOI: 10.1001/jamaoncol.2019.0393.

9.Losurdo G, Angelillo D, Favia N, et al. Checkpoint inhibitor-induced colitis: an update[J]. Biomedicines, 2023, 11(5): 1496. DOI: 10.3390/biomedicines11051496.

10.李玥, 王汉萍, 郭潇潇, 等. 免疫检查点抑制剂相关消化系统不良反应的临床诊治建议[J]. 中国肺癌杂志, 2019, 22(10): 661-665. [Li Y, Wang HP, Guo XX, et al. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related gastrointestinal adverse reactions[J]. Chinese Journal of Lung Cancer, 2019, 22(10): 661-665.] DOI: 10.3779/j.issn.1009-3419.2019.10.10.

11.杜伟, 孙巍, 顾建华, 等. 升血小板胶囊致药疹1例[J].临床肺科杂志, 2009, 14(7): 928. [Du W, Sun W, Gu JH,et al. Erythrocyte platelet-raising capsules causing drug eruption in a case[J]. Journal of Clinical Pulmonology, 2009, 14(7): 928.] DOI: 10.3969/j.issn.1009-6663.2009.07.071.

12.贾旭晨, 许妍妍, 李遇伯, 等. 复方青黛制剂及单味药的毒性研究进展[J]. 中草药, 2023, 54(24): 8282-8289. [Jia XC, Xu YY, Li YB, et al. Advances in the toxicological research of compound Qingdai preparations and single herbs[J]. Chinese Journal of Traditional Medicine, 2023, 54(24): 8282-8289.] DOI: 10.7501/j.issn.0253-2670.2023.24.033.

13.索宝军, 周丽雅, 丁士刚, 等. 青黛相关缺血性结肠黏膜损伤的内镜及临床特点分析[J]. 中华内科杂志, 2011, 50(8): 646-649. [Suo BJ, Zhou LY, Ding SG, et al. The endoscopic and clinical features of indigo naturalis-associated ischemic lesions of colonic mucosa[J]. Chinese Journal of Internal Medicine, 2011, 50(8): 646-649.] DOI: 10.3760/cma.j.issn.0578-1426.2011.08.010.

14.Brandt LJ, Feuerstadt P, Longstreth GF, et al.ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI)[J]. Am J Gastroenterol, 2015, 110(1): 18-44; quiz 45. DOI: 10.1038/ajg.2014.395.

15.蒋凤琴, 何卫美, 汪荣华. 升血小板胶囊致缺血性结肠炎2例分析[J]. 药物流行病学杂志, 2022, 31(12): 858-860. [Jiang FQ, He WM, Wang RH. Analysis of two cases of ischemic colitis caused by platelet-raising capsules[J]. Chinese Journal of Pharmacoepidemiolog, 2022, 31(12): 858-860.] DOI: 10.19960/j.cnki.issn1005-0698.2022.12.016.

16.陈英, 李相生, 葛淑静, 等. 高龄老年缺血性肠病45例临床特点分析[J]. 空军医学杂志, 2021, 37(4): 328-330, 334. [Chen Y, Li XS, Ge SJ, et al. Clinical characteristics analysis of 45 cases of ischemic intestinal disease in elderly patients[J]. Air Force Medical Journal, 2021, 37(4): 328-330, 334.] DOI: 10.3969/j.issn.2095-3402.2021.04.015.

17.贾国青, 李春涛. 丹参酮联合前列地尔治疗缺血性肠病患者的疗效及对血清肠脂肪酸结合蛋白与D-二聚体的影响 [J]. 中国药物经济学, 2023, 18(4): 62-64, 68. [Jia GQ, Li CT. Efficacy of salvia miltiorrhiza lactone combined with prostaglandin E1 in treating patients with ischemic intestinal disease and its effects on serum intestinal fatty acid binding protein and D-dimer [J]. China Journal of Pharmaceutical Economics, 2023, 18(4): 62-64, 68.] DOI: 10.12010/j.issn.1673-5846.2023.04.013.

18.Huguier M, Barrier A, Boelle PY, et al Ischemic colitis. Am J Surg. 2006 Nov, 192(5): 679-684. DOI: 10.1016/j.amjsurg.2005.09.018.

19.张志清, 苏秀琴, 郭进, 等. 复方青黛丸对消化系统的损害 [J].药物不良反应杂志, 2001, 3(2): 111-113. [Zhang ZQ, Su XQ, Guo J, et al. Damage of compound Qingdai pill to the digestive system[J]. Journal of Adverse Drug Reactions, 2001, 3(2): 111-113.] DOI: 10.3969/j.issn.1008-5734.2001.02.013.

20.王彩花, 金丹, 张晗芸, 等. 升血小板胶囊致缺血性肠炎一例[J]. 中华消化杂志, 2014, (10): 704-705. [Wang CH, Jin D, Zhang HH, et al. A case of ischemic enteritis caused by Shengxue tablets[J]. Chinese Journal of Digestion, 2014, (10): 704-705.]DOI: 10.3760/cma.j.issn.0254-1432.2014.10.013.